BioSpace News Archive

Pharm Country

Tonix Pharmaceuticals Announces Collaboration with Boston Children’s Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in Animals

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that it has entered into a sponsored research agreement with Boston Children’s Hospital to study TNX-15001 for the prevention of graft-versus-host disease after hematopoietic stem cell transplantation in animals.

December 5, 2022
·
8 min read
BioMidwest

BIO-TECHNE RELEASES MITOBRILLIANT™ FLUORESCENT DYES, PROVIDING A NEXT-GENERATION TOOL FOR IMAGING MITOCHONDRIA IN LIVE AND FIXED CELLS

Bio-Techne Corporation (NASDAQ: TECH) today announced the introduction of MitoBrilliant ™ probes.

December 5, 2022
·
2 min read
Deals

Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance

Windtree Therapeutics, Inc. today announced that the NASDAQ Stock Market (“Nasdaq”) has granted Windtree an additional 180 days to regain compliance with Nasdaq’s $1.00 minimum bid price rule requirement under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).

December 5, 2022
·
5 min read
Business

iSpecimen Appoints Joseph J. Basile to Board of DirectorsSought-After Strategic Advisor Brings Expertise in Mergers and Acquisitions, Restructuring and Governance to iSpecimen

iSpecimen Inc. announced today that the Company has appointed Joseph J. Basile to iSpecimen’s Board of Directors (the “Board”), as well as the audit committee and the nominating and corporate governance committee of the Company, effective November 28, 2022.

December 5, 2022
·
4 min read
Genetown

Organogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference

Organogenesis Holdings Inc. today announced that company management will participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference.

December 5, 2022
·
1 min read
Biotech Beach

Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for review of tofersen, an investigational medicine for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).

December 5, 2022
·
5 min read
Biotech Bay

SonoThera™ Completes $60.75M Series A Funding for Ultrasound-Guided, Nonviral Gene Therapy Platform Development

Lead investor ARCH Venture Partners is joined by Illumina Ventures, Johnson & Johnson Innovation – JJDC, Inc., Vertex Ventures HC, Medical Excellence Capital and others in global biotechnology and pharmaceutical investment.

December 5, 2022
·
3 min read
Drug Development

BrainTale Has Presented the Interest If Its Digital Biomarkers Platform in Differential Diagnosis During the 15th Edition of Clinical Trials on Alzheimer’s Disease Conference

BrainTale has presented the “Evaluation of a clinically validated digital platform to provide Diffusion MRI biomarkers in Alzheimer’s disease” during the 15th edition of the Clinical Trials on Alzheimer’s Disease conference (CTAD 2022) held in San Francisco and online from November 29 to December 2, 2022.

December 5, 2022
·
3 min read
Drug Development

Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis

Cogent Biosciences, Inc. today announced the details of its investor webcast being held on Monday, December 12, 2022 at 8:00 a.m. ET (7:00 a.m. CT) to discuss updated clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis.

December 5, 2022
·
1 min read
Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S announced that the U.S. Food & Drug Administration has allowed the Company to initiate an expanded access program for its investigational parathyroid hormone replacement therapy, TransCon PTH, for adult patients with hypoparathyroidism.

December 5, 2022
·
5 min read